Core Viewpoint - Metsera's ultra-long-acting GLP-1 receptor agonist MET097 has entered the critical phase of global weight loss drug competition with its Phase 3 clinical trial registration, following its acquisition by Pfizer, indicating a strategic move in the metabolic disease sector [5][9]. Group 1: Clinical Trial Details - The VESPER-4 trial is a large-scale, randomized, controlled Phase 3 study involving 3,500 participants with obesity or overweight, expected to complete preliminary research by September 2027 [6][8]. - The trial will assess the efficacy and safety of MET097, administered via weekly subcutaneous injections, with the primary endpoint being weight reduction after 64 weeks of continuous treatment [7][8]. Group 2: Pharmacokinetics and Administration - MET097 has a half-life of 18 days, suggesting potential for monthly dosing regimens, which could enhance patient compliance and optimize real-world usage scenarios [9]. - Despite its potential for longer dosing intervals, the initial Phase 3 trial will utilize a weekly administration schedule, reflecting Pfizer's balance between regulatory risks and commercial aggressiveness [10]. Group 3: Competitive Landscape - Pfizer's acquisition of Metsera and the development of MET097 represent a strategic entry into the GLP-1 weight loss market, where competitors like Novo Nordisk and Eli Lilly have established significant product and market barriers [10].